As South Africa becomes the ninth African country to introduce the use of new long-acting drug lenacapavir for HIV prevention, RFI spoke with infectious disease specialist Ndong Essomba Bitchoka about how the treatment works, whether the supply will meet demand and why developing an HIV vaccine remains a challenge.
New long-acting antiretroviral treatment lenacapavir requires just two injections a year, reducing the need for daily pills. But questions remain over access, cost and whether enough doses will be available to meet demand in the country with the world's largest HIV-positive population.
